More recently, THZ1, a selective CDK7 covalent inhibitor, has been shown to be effective in reducing the expression of super-enhancer associated genes and inhibiting the growth of multiple cancers such as small cell lung cancer [15], MYCN-driven neuroblastoma cells [16], and triple-negative breast cancer [17]. Here, CDK7 is linked to small cell lung carcinoma.